title: A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
abstract: Several metastasizing murine and human animal models for prostate cancer are available. However, these models are androgen-independent and lack differentiated features such as androgen receptor and androgen-regulated gene expression like prostate-specific antigen (PSA). The objective of this study was to develop a metastasizing prostate cancer model with differentiated features using the human LNCaP cell line. Athymic and SCID mice were injected either s.c. or intraprostatically with 1 x 10(6) LNCaP cells. Changes in serum and tumor PSA mRNA levels were determined before and after castration to assess time to androgen-independent progression. Local tumor and metastatic growth was assessed at sacrifice after 12 weeks. Reverse transcription-PCR (RT-PCR) was used to detect circulating LNCaP cells. LNCaP tumor incidence after s.c. injection was 100% (65 of 65) in SCID mice and 80% in athymic mice. No lymph node or distant metastases were observed with s.c. tumors, and RT-PCR for PSA transcripts was negative. Primary tumor incidence after intraprostatic injection was 89% (39 of 44) in SCID mice and 60% in athymic mice. In 10 SCID mice with primary tumors followed for 12 weeks, retroperitoneal or mediastinal lymph node metastases were found in 100%, and microscopic pulmonary metastases were identified in 40%. RT-PCR for PSA transcripts was positive in 3 of 10 mice tested. Serum PSA levels in mice with s.c. and intraprostatic tumors decreased by 65% to nadir levels at 7 and 4 days after castration, respectively. Serum PSA and LNCaP tumor PSA mRNA levels increased to precastration levels earlier in SCID mice with intraprostatic tumors compared to those with s.c. tumors. Intraprostatic injection of LNCaP cells in SCID mice provides a useful animal model to investigate mechanisms of metastasis and to evaluate therapies targeted toward inhibiting the metastatic cascade.
authors.affiliation: Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Sato
authors.forename: M E
authors.initials: ME
authors.lastname: Gleave
authors.forename: N
authors.initials: N
authors.lastname: Bruchovsky
authors.forename: P S
authors.initials: PS
authors.lastname: Rennie
authors.forename: E
authors.initials: E
authors.lastname: Beraldi
authors.forename: L D
authors.initials: LD
authors.lastname: Sullivan
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D004195:Disease Models, Animal; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016513:Mice, SCID; D009363:Neoplasm Proteins / Q000097:blood* / Q000235:genetics; D009368:Neoplasm Transplantation; D009919:Orchiectomy; D016133:Polymerase Chain Reaction; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D012333:RNA, Messenger / Q000097:blood; D012186:Retroperitoneal Neoplasms / Q000097:blood / Q000556:secondary*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D009363:Neoplasm Proteins; D012333:RNA, Messenger; D017430:Prostate-Specific Antigen